Overview

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

Status:
Withdrawn

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

This randomized, open-label, multicenter study will evaluate the efficacy and safety of navitoclax in addition to bendamustine and rituximab in patients with relapsed diffuse large B-cell lymphoma. Patients will be randomized to receive navitoclax in addition to bendamustine and rituximab or bendamustine and rituximab alone for 6 cycles.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

AbbVie (prior sponsor, Abbott)

Treatments:

Bendamustine Hydrochloride
Navitoclax
Rituximab